Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | QPCT | Q16769 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071592 | 0.94 | MAP2 (0.56) | MAP2MEN1KMT2APOLBRAB9A | |
| Trifluoroacetic Acid SCHEMBL1882867 | 0.90 | MAP2 (0.48) | MAP2MEN1KMT2APOLBMAPT | |
| Trifluoroacetic Acid SCHEMBL1880238 | 0.89 | MAP2 (0.52) | MAP2RAB9AMAPTLMNAKDR | |
| Trifluoroacetic Acid SCHEMBL1883581 | 0.86 | MAP2 (0.55) | MAP2KMT2ACYP3A4FGFR1KDR | |
| Trifluoroacetic Acid SCHEMBL1876323 | 0.84 | MAP2 (0.53) | MAP2MEN1KMT2ARAB9AL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL1880747 | 0.84 | MAP2 (0.55) | MAP2MEN1KMT2APOLBRAB9A | |
| SCHEMBL4075141 | 0.83 | MAP2 (0.51) | MAP2MEN1KMT2APOLBMAPT | |
| SCHEMBL1877183 | 0.83 | MAPT (0.51) | MAP2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL1881221 | 0.83 | MAP2 (0.60) | MAP2MEN1KMT2APOLBRAB9A | |
| SCHEMBL1881761 | 0.83 | MAP2 (0.56) | MAP2MEN1KMT2APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947706-B2 | Anticancer agents; modulate kinases such as KDR (Kinase insert Domain Receptor and Tie-2 (TEK) , a member of the tyrosine kinase receptor family; 3-{4-[3-(2-methoxyphenyl)ureido]phenyl}-1H-pyrrolo[2,3-b]pyridine-2-carboxamide for example | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-05-24 | — | — | US | claimed |
| EP-1877409-B1 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2009-06-17 | — | — | EP | claimed |
| US-20080139606-A1 | Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-12 | — | — | US | claimed |
| US-7947706-B2 | Anticancer agents; modulate kinases such as KDR (Kinase insert Domain Receptor and Tie-2 (TEK) , a member of the tyrosine kinase receptor family; 3-{4-[3-(2-methoxyphenyl)ureido]phenyl}-1H-pyrrolo[2,3-b]pyridine-2-carboxamide for example | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-05-24 | — | — | US | disclosed |
| US-20080139606-A1 | Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139606-A1 | Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof | WEE1, CNKSR1, WEE2 | MAP2 1477/4885MEN1 2890/4885KMT2A 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.